Imagine a giant, shared digital library where doctors and scientists from different countries can instantly swap notes on how a virus is changing. Instead of everyone keeping their own secret files, they use a common system to spot dangerous new variants quickly. It's like a global early-warning system that helps everyone prepare for the next big health scare before it happens.
Fragmented health data across different countries and disciplines slows down the response to virus mutations. This delay prevents the rapid development of updated vaccines and diagnostic tests.
A general-purpose Pathogens Portal and a Pathogen Data Hub for storing, linking, and analyzing viral and clinical data.
If you are a vaccine developer dealing with rapidly mutating virus strains — this project developed a Pathogens Portal that provides raw viral sequences. This allows you to identify variants of concern faster to update your formulas.
If you are a data analytics firm dealing with fragmented clinical records across borders — this project developed federated data tools that allow analysis without moving sensitive data. This helps you build compliant tools for public health action.
If you are a diagnostic company dealing with outdated test targets — this project developed a system for tracking viral sequences. This ensures your tests remain effective against the latest versions of the virus.
Based on available project data, the project focuses on open data and the European Open Science Cloud, suggesting the primary outputs are open-access rather than priced products.
Yes, the project evolved from a COVID-19 focus to a general purpose Pathogens Portal designed for future pandemic preparedness and other infectious diseases.
Based on available project data, the project emphasizes FAIR and open data sharing, though specific commercial licenses for the digital tools are not detailed.
The project developed federated data analysis specifically to conform with data protection regulations and aligns with the European Health Data Space.
The project period runs from 2021-10-01 to 2024-09-30, indicating the tools are currently in the final stages of development or deployment.
The consortium is heavily weighted toward research and academia, featuring 31 research organizations and 20 universities. With only 1 industry partner and 2 SMEs (a 2% industry ratio), the project is primarily a public-sector infrastructure effort. However, the scale of 55 partners across 20 countries indicates a high level of international standardization and validation.
Contact the European Molecular Biology Laboratory (EMBL) regarding Pathogen Portal access.
Contact us to find specific data sets from the BY-COVID Pathogens Portal for your R&D pipeline.
